Scarica l'app Stockscreener
14.22
6.26%
-0.95
Dopo l'orario di chiusura:
14.22
Compass Pathways Plc Adr Borsa (CMPS) Ultime notizie
Fluence to develop psilocybin therapy training for Compass - Investing.com
Compass Pathways Announces U.S. Grant Program Recipients for the Development of Post-Approval COMP360 Provider Training - Finviz
symbol__ Stock Quote Price and Forecast - CNN
Compass Pathways Forecast: Breakout Could Target $22.51–$25.51 - FXEmpire
Compass Pathfinder Limited: Compass Pathways' New 52-Week Topline Open-Label Data from Phase 3 COMP005 Trial Demonstrates Additional Benefit from Another COMP360 Dose in Part C Extending Durability Out to 1 Year - FinanzNachrichten.de
Compass Pathways stock hits 52-week high at 15.4 USD - Investing.com
Compass Pathways stock shows durable results in depression trial - Investing.com
COMPASS Pathways (CMPS) Nears FDA Filing for COMP360 Following a Valuation Question - Sahm
Compass Pathways Target of Unusually High Options Trading (NASDAQ:CMPS) - MarketBeat
How COMPASS Pathways’ VA Psilocybin Trial (CMPS) Has Reframed Its Veteran Mental Health Ambitions - Sahm
Compass Pathways Targets 2027 COMP360 Launch as FDA Filing Advances - Yahoo Finance
Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
COMPASS Pathways plc (CMPS) stock price, news, quote and history - Yahoo Finance UK
HC Wainwright Cuts Earnings Estimates for Compass Pathways - MarketBeat
COMPASS Pathways (CMPS) Stock Looks Stretched Following Its 214% One Year Run - Sahm
COMPASS Pathways plc (5Y6.F) stock price, news, quote and history - Yahoo Finance Singapore
Renaissance Technologies LLC Reduces Stock Position in Compass Pathways PLC Sponsored ADR $CMPS - MarketBeat
Compass Pathways partners with VA on psilocybin trial for veterans - Investing.com
Compass Pathfinder Limited: Compass Pathways Working with U.S. Department of Veterans Affairs for Investigational Study of Psilocybin - FinanzNachrichten.de
Compass Pathways (NASDAQ:CMPS) Trading 9.8% HigherWhat's Next? - MarketBeat
Earnings call transcript: COMPASS Pathways advances q2 2026 launch plans as stock slips - Investing.com
COMPASS Pathways Reports Q2 2026 Financials and Updates on COMP360 Clinical Programs - Kalkine Media
Why is Compass Pathways stock rallying today? By Investing.com - Investing.com South Africa
Compass Pathways Q2 Earnings Call Highlights - Yahoo Finance
Seven Fleet Capital Management LP Buys 118,021 Shares of Compass Pathways PLC Sponsored ADR $CMPS - MarketBeat
200,000 Shares in Compass Pathways PLC Sponsored ADR $CMPS Acquired by Vivo Capital LLC - MarketBeat
Compass Pathways earnings on deck ahead of pivotal FDA filing - Investing.com
Eversept Partners LP Makes New $3.75 Million Investment in Compass Pathways PLC Sponsored ADR $CMPS - MarketBeat
Orbimed Advisors LLC Buys New Shares in Compass Pathways PLC Sponsored ADR $CMPS - MarketBeat
Affinity Asset Advisors LLC Purchases 908,483 Shares of Compass Pathways PLC Sponsored ADR $CMPS - MarketBeat
COMPASS Pathways plc (CMPS) Stock Price, News, Quote & History - Yahoo! Finance Canada
Cathie Wood Swaps Robinhood for SpaceX, Archer—Did ARK Pivot Back to Moonshot Innovation? - Sahm
Amova Asset Management Americas Inc. Has $2.03 Million Holdings in Compass Pathways PLC Sponsored ADR $CMPS - MarketBeat
A Depression Drug Just Cleared a Key Hurdle Early, and the Market for New Mental Health Treatments Keeps Widening - Sahm
Compass Pathways (NASDAQ:CMPS) Trading Down 5.5%Here's Why - MarketBeat
Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
AtaiBeckley surges after report Lilly poised to buy psychedelic drug developer - Sahm
COMPASS Pathways (CMPS) Is Down 8.6% After Phase 3 Durability Data For COMP360 In TRD - Yahoo Finance
Compass Pathways study shows minimal interaction in psilocybin trials By Investing.com - Investing.com South Africa
Compass Pathways study shows minimal interaction in psilocybin trials - Investing.com
Should COMP360’s Durable Phase 3 Results and FDA Momentum Require Action From COMPASS Pathways (CMPS) Investors? - Sahm
Compass Pathways (NASDAQ:CMPS) Shares Gap UpTime to Buy? - MarketBeat
Compass Pathways Eyes 2027 Launch as Psilocybin Depression Data Holds Up - Yahoo Finance
Compass Pathways stock reiterated Buy at H.C. Wainwright after trial data - Investing.com
Compass Pathways stock falls on Phase 3 trial data release By Investing.com - Investing.com South Africa
Compass Pathways stock falls on Phase 3 trial data release - Investing.com
Compass Pathways reports 6-month data from phase 3 TRD trial - Investing.com
Why is Compass Pathways stock gaining today? By Investing.com - Investing.com South Africa
Why is Compass Pathways stock gaining today? - Investing.com
Is AtaiBeckley Stock Worth Buying After Its Stronger Rally in 2026? - TradingView
AtaiBeckley Stock Outlook Depends on Key Pipeline Catalysts in 2026 - TradingView
Enterprise value to EBIT forward of COMPASS Pathways Plc Sponsored ADR – MUN:5Y6 - TradingView
Compass Pathways stock hits 52-week high at 14.77 USD By Investing.com - Investing.com South Africa
Compass Pathways stock hits 52-week high at 14.77 USD - Investing.com
COMPASS Pathways Plc Sponsored ADR Actuals & Estimates (NASDAQ:CMPS) - TradingView
3.01%
0.80%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):